Novartis
Novartis and Versant Ventures Launch Borealis Biosciences to Develop RNA Medicines for Kidney Diseases
Borealis Biosciences, Novartis, Versant Ventures, RNA medicines, kidney diseases, xRNA technology, biotechnology, startup, kidney research, RNA therapeutics.
Novartis and Versant Invest $150M in Kidney Biotech Borealis to Replicate Chinook’s Success
Novartis, Versant, Borealis, kidney biotech, $150M investment, Chinook Therapeutics, chronic kidney disease, biotech funding
Novartis Fails to Block MSN’s Entresto Generic Launch
Novartis, Entresto, MSN Pharmaceuticals, generic drugs, patent infringement, FDA approval
Novartis’ Fabhalta Clinches Another FDA Win, This Time in IgA Nephropathy
Novartis, Fabhalta, FDA approval, IgA nephropathy, proteinuria reduction, complement inhibitor, kidney disease
Novartis Intensifies Entresto Defense with FDA Complaint Amid Patent Lawsuits
Novartis, Entresto, FDA complaint, patent lawsuits, pharmaceuticals
Novartis Sues FDA Over Approval of Entresto Generic After Petition Rejection
Novartis, FDA, Entresto, generic drug, lawsuit, patent exclusivity, heart failure medication
Novartis Partners with Dren Bio in $3 Billion Deal for Targeted Myeloid Engagers
Novartis, Dren Bio, Myeloid Engagers, Biotech, Pharmaceutical, Alliance, $3 Billion Deal
Novartis to Wind Down San Diego Technical Research and Development Site by Mid-2025
Novartis, San Diego, Technical Research and Development, Site Closure, Layoffs, Restructuring
Italian Antitrust Agency Investigates Novartis, Biogen, and Others Over Lucentis Biosimilar
Italian Competition Authority, Novartis, Biogen, Samsung Bioepis, Genentech, Lucentis, Byooviz, Biosimilar, Antitrust Probe
Novartis Advances Remibrutinib for Chronic Spontaneous Urticaria with Promising Long-term Data
Novartis, Remibrutinib, Chronic Spontaneous Urticaria, Phase III Trials, Long-term Data, Oral Treatment, Bruton’s Tyrosine Kinase Inhibitor